Evaluation of the Telehealth Integrated Care Model in Patients With Hyperlipidemia and Other Cardiometabolic Disease
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 1,302
- 试验地点
- 1
- 主要终点
- changes of compliance rate of target treatment for hyperlipidemia
研究概览
简要总结
The objective of this study is to evaluate the telehealth integrated care model for its clinical efficacy, medical resource utilization, health economics measurement, and satisfaction survey indicators in hyperlipidemia patients and other cardiometabolic diseases. The result of the study will provide evidence for the value of integrated model in the treatment of patients with cardiometabolic syndrome.
详细描述
Efficacy evaluation is critical for understanding the practical application effect of telehealth integrated mode in the therapy of cardiometabolic disease patients. We can comprehend the influence of the combination of online and offline models on patients' clinical curative effect, medication compliance, medical cost, and satisfaction by analyzing the curative effect and finding a scientific basis for clinical practice and policy formation. As a result, the purpose of this study is to assess the curative effect of hyperlipidemia patients with other cardiometabolic disease using a telehealth integrated model, as well as to investigate the potential benefits and risks of this model in the management of cardiometabolic disease.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 16 Years 至 85 Years（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age ≥ 16 years, and ≤ 85 years;
- •Diagnosis as hyperlipidemia with at least one of the following disease: hypertension or type 2 diabetes mellitus;
- •Agreed to be enrolled in this study.
排除标准
- •Undergone percutaneous coronary intervention within one year in our hospital;
- •Severe LV dysfunction, such as LV ejection fraction < 35%, or congestive heart failure with New York Heart Association (NYHA) functional class IV or Killip class IV;
- •Structural heart disease, or severe arrhythmia;
- •Severe liver or kidney diseases, endocrinology diseases, hematologic diseases, rheumatic immune system diseases, and malignancy;
- •could not complete at least one-year-followup.
结局指标
主要结局
changes of compliance rate of target treatment for hyperlipidemia
时间窗: 12 month after recuitment
difference of compliance rate of target treatment for hyperlipidemia between endpoint with baseline
次要结局
- changes of blood pressure(12 month after recuitment)
- changes of glycosylated hemoglobin(12 month after recuitment)
- changes of fasting glucose(12 month after recuitment)
- changes of LDL-c(12 month after recuitment)
- changes of triglyceride(12 month after recuitment)
- abnormal liver function(12 month after recuitment)
- abnormal kidney function(12 month after recuitment)
- Cardiovascular death(12 month)
- medication adherence rate(12 month)
- patients satisfaction(12 month)
- in person visit counts(12 month after recuitment)
- Rehospitalization(12 month)
- medical cost(12 month)
- telehealth visit counts(12 month after recuitment)
研究者
Zeng Lin, Ph. D.
Deputy Director of Research Center of Clinical Epidemiology
Peking University Third Hospital